Please assess the completion status of the following clinical trial:

Trial Title: To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Provision of written informed consent prior to any study specific procedures~2. Male or female aged ≥18 years~3. Histological or cytological confirmation of any malignant solid tumour in an advanced or metastatic setting who meet one of the criteria below:~   * Patients should be resistant or refractory to standard treatment if such treatment exists OR~  * Patients for which no suitable effective standard therapy exists OR~  * Patients with advanced breast cancer for whom anastrozole, letrozole or tamoxifen are indicated may also enter the study (postmenopausal breast cancer patients will be eligible for any of the cohorts; however, premenopausal breast cancer patients will be eligible for the tamoxifen cohort only).~4. Patients must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment as defined below:~   * Haemoglobin (Hb) ≥10.0 g/dL with no blood transfusions in the past 28 days~  * Absolute neutrophil count (ANC) ≥1.5 x 109/L~  * Platelet count ≥100 x 109/L~  * Total bilirubin ≤1.5 x institutional upper limit of normal (ULN) (except in the case of Gilbert's disease)~  * Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤2.5 x institutional ULN unless liver metastases are present, in which case they must be ≤5x ULN~  * Serum creatinine ≤1.5 x institutional ULN~5. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2~6. Patients must have a life expectancy ≥16 weeks~7. Evidence of non-childbearing status for women of childbearing potential, or postmenopausal status: negative urine or serum pregnancy test within 28 days of study treatment, confirmed prior to treatment on Day 1 of Part A.~   Postmenopausal is defined as:~  * Age ≥ 60 years~  * Age \<60 years and amenorrheic for 1 year or more in the absence of chemotherapy and/or hormonal treatment~  * Luteinising hormone (LH), follicle stimulating hormone (FSH) and plasma oestradiol levels in the postmenopausal range for women under 60 years~  * Radiation-induced oophorectomy with last menses \>1 year ago~  * Or surgical sterilisation (bilateral oophorectomy or hysterectomy)~8. Patients are willing and able to comply with the protocol for the duration of the study including undergoing treatment, and scheduled visits and examinations~9. Patients must be on stable concomitant medication regimen (with the exception of electrolyte supplements), defined as no change in medication or dose within 2 weeks prior to start of study treatment.~Exclusion Criteria:~1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff, its agents, and/or staff at the study site)~2. Previous enrolment in the present study~3. Exposure to an investigational product (IP) (including PARP inhibitor) within 30 days or 5 half lives (whichever is the longer) prior to enrolment~4. Prior chemotherapy within 3 weeks of study entry~5. Prior radiotherapy within 2 weeks of study entry~6. If prior endocrine treatment is given, adequate washout period is required: at least 2 weeks for anastrozole, at least 4 weeks for letrozole and at least 10 weeks for tamoxifen~7. Resting ECG with QTc \>470 msec detected on 2 or more time points within a 24 hour period, or family history of long QT syndrome. If ECG demonstrates QTc \>470 msec, patient will be eligible only if repeat ECG demonstrates QTc \<470 msec.~8. Patients who are receiving inhibitors or inducers of CYP3A4 unless washed out prior to start of study treatment.~9. Persistent toxicities (Common Toxicity Criteria for Adverse Events \[CTCAE\] grade ≥2) caused by previous cancer therapy, excluding alopecia and/or CTCAE grade 2 peripheral neuropathy~10. Patients with myelodysplastic syndrome/acute myeloid leukaemia~11. Major surgery within 2 weeks of starting study treatment: patients must have recovered from any effects of any major surgery~12. Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled seizures or active uncontrolled infection.~13. Patients unable to swallow orally administered medication and patients with gastrointestinal disorders or significant gastrointestinal resection likely to interfere with absorption of the study medication~14. Patients who have gastric, gastro-oesophageal, or oesophageal cancer~15. Pregnant or breastfeeding women~16. Patients with known active Hepatitis B or C, or human immunodeficiency virus (HIV).~17. Patients with a known hypersensitivity to olaparib (all cohorts), tamoxifen (Cohort 1) anastrozole (Cohort 2), letrozole (Cohort 3), or any of the excipients of these products.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 - Tamoxifen (Type: EXPERIMENTAL): Olaparib-alone Steady state PK, Tamoxifen-alone steady state PK, Combined olaparib and Tamoxifen steady state PK.
- Cohort 2 - Anastrozole (Type: EXPERIMENTAL): Olaparib-alone Steady state PK, Anastrozole-alone steady state PK, Combined olaparib and Anastrozole steady state PK.
- Cohort 3 - Letrozole (Type: EXPERIMENTAL): Olaparib-alone Steady state PK, Letrozole-alone steady state PK, Combined olaparib and Letrozole steady state PK.

Based on this trial design, predict the completion outcome and termination type (if applicable).